Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
https://www.zacks.com/stock/news/2319589/gilead-gild-q2-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2319589
Aug 08, 2024 - The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
Gilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates
https://www.zacks.com/stock/news/2319503/gilead-sciences-gild-q2-earnings-and-revenues-beat-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2319503
Aug 08, 2024 - Gilead (GILD) delivered earnings and revenue surprises of 24.84% and 4.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
0
Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2317343/voyager-therapeutics-vygr-reports-q2-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2317343
Aug 06, 2024 - Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 52.63% and 156.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
0
Gilead Sciences (GILD) Advances While Market Declines: Some Information for Investors
https://www.zacks.com/stock/news/2314711/gilead-sciences-gild-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2314711
Aug 01, 2024 - Gilead Sciences (GILD) closed the most recent trading day at $76.49, moving +0.57% from the previous trading session.
0
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
https://www.zacks.com/stock/news/2306431/gilead-sciences-gild-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2306431
Jul 22, 2024 - Gilead Sciences (GILD) reachead $72.41 at the closing of the latest trading day, reflecting a -0.21% change compared to its last close.
0
Top Analyst Reports for Abbott, BP & Gilead
https://www.zacks.com/commentary/2291545/top-analyst-reports-for-abbott-bp-gilead?cid=CS-ZC-FT-research_daily-2291545
Jun 21, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), BP p.l.c. (BP) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks Smith-Midland Corporation (SMID) and Crimson Wine Group, Ltd. (CWGL).
0
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2288139/gilead-sciences-gild-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2288139
Jun 13, 2024 - The latest trading day saw Gilead Sciences (GILD) settling at $63.56, representing a -1.21% change from its previous close.
0
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
https://www.fool.com/investing/2024/06/08/3-stocks-with-mouthwatering-dividends-you-can-buy/?source=iedfolrf0000001
Jun 08, 2024 - These stocks offer great dividends and more.
0
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
https://www.zacks.com/stock/news/2282965/gilead-gild-rcus-announce-data-from-colorectal-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2282965
Jun 03, 2024 - Gilead (GILD) and partner Arcus Biosciences (RCUS) present data from metastatic colorectal cancer and gastrointestinal cancer study.
0
Top Stock Reports for NextEra Energy, BP & Gilead Sciences
https://www.zacks.com/commentary/2282779/top-stock-reports-for-nextera-energy-bp-gilead-sciences?cid=CS-ZC-FT-research_daily-2282779
Jun 03, 2024 - Today's Research Daily features new research reports on 16 major stocks, including NextEra Energy, Inc. (NEE), BP p.l.c. (BP) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks Hamilton Beach Brands Holding Company (HBB) and FONAR Corporation (FONR).
0